FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107931499> ?p ?o ?g. }

• W2107931499 endingPage "154" @default.
• W2107931499 startingPage "148" @default.
• W2107931499 abstract "Objective: Patients with ischemic stroke treated with tissue plasminogen activator (rt-PA) have better outcomes when treated closer to the time of symptom onset and within the 3-hour window. We previously demonstrated the clinical use of TeleBAT, a mobile telemedicine system for stroke. We tested the impact of that system on time to treatment for patients with acute stroke. Methods: Validity and reliability were tested by comparing neurologic examination scores obtained using our wireless system, which transmits video of a patient from a moving ambulance to desktop computers, with those obtained using the National Institute of Neurological Disorders and Stroke training videotape. TeleBAT validity and good interrater reliability were defined a priori as a kappa statistic of r > 0.5. We compared the average time to treatment for our TeleBAT-evaluated intervention group with that for our control group. The intervention group consisted of two actor patients with stroke mimicking 12 stroke scenarios and evaluated using TeleBAT. The control group consisted of patients with stroke evaluated and treated with rt-PA on arrival to the emergency department. Data were analyzed using standard t test. Results: National Institutes of Health Stroke Scale items calculated by the neurologists suggest TeleBAT is valid for assessing patients with stroke remotely. Interrater reliability was high: the neurologists gleaned the same information from TeleBAT transmissions. Kappa values for both validity and reliability exceeded 0.5. The mean time to treatment for patients assessed by TeleBAT was 17 ± 4 minutes compared with 33 ± 17 minutes for our control group (P = .0033). Conclusion: TeleBAT seems to be a valid and reliable means of evaluating stroke neurologic deficits. Time to treatment was shortened using ambulance transport time to evaluate patients as candidates for thrombolytic therapy. Future studies should use a randomized design with patients with acute stroke. Objective: Patients with ischemic stroke treated with tissue plasminogen activator (rt-PA) have better outcomes when treated closer to the time of symptom onset and within the 3-hour window. We previously demonstrated the clinical use of TeleBAT, a mobile telemedicine system for stroke. We tested the impact of that system on time to treatment for patients with acute stroke. Methods: Validity and reliability were tested by comparing neurologic examination scores obtained using our wireless system, which transmits video of a patient from a moving ambulance to desktop computers, with those obtained using the National Institute of Neurological Disorders and Stroke training videotape. TeleBAT validity and good interrater reliability were defined a priori as a kappa statistic of r > 0.5. We compared the average time to treatment for our TeleBAT-evaluated intervention group with that for our control group. The intervention group consisted of two actor patients with stroke mimicking 12 stroke scenarios and evaluated using TeleBAT. The control group consisted of patients with stroke evaluated and treated with rt-PA on arrival to the emergency department. Data were analyzed using standard t test. Results: National Institutes of Health Stroke Scale items calculated by the neurologists suggest TeleBAT is valid for assessing patients with stroke remotely. Interrater reliability was high: the neurologists gleaned the same information from TeleBAT transmissions. Kappa values for both validity and reliability exceeded 0.5. The mean time to treatment for patients assessed by TeleBAT was 17 ± 4 minutes compared with 33 ± 17 minutes for our control group (P = .0033). Conclusion: TeleBAT seems to be a valid and reliable means of evaluating stroke neurologic deficits. Time to treatment was shortened using ambulance transport time to evaluate patients as candidates for thrombolytic therapy. Future studies should use a randomized design with patients with acute stroke." @default.
• W2107931499 created "2016-06-24" @default.
• W2107931499 creator A5008114238 @default.
• W2107931499 creator A5018826785 @default.
• W2107931499 creator A5023160611 @default.
• W2107931499 creator A5034956444 @default.
• W2107931499 creator A5057046852 @default.
• W2107931499 creator A5064484919 @default.
• W2107931499 creator A5074376265 @default.
• W2107931499 creator A5077011016 @default.
• W2107931499 creator A5077909900 @default.
• W2107931499 date "2004-07-01" @default.
• W2107931499 modified "2023-10-15" @default.
• W2107931499 title "Shortening time to stroke treatment using ambulance telemedicine: TeleBAT" @default.
• W2107931499 cites W2027123157 @default.
• W2107931499 cites W2030853535 @default.
• W2107931499 cites W2096567497 @default.
• W2107931499 cites W2121471658 @default.
• W2107931499 cites W2155758555 @default.
• W2107931499 doi "https://doi.org/10.1016/j.jstrokecerebrovasdis.2004.03.004" @default.
• W2107931499 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17903967" @default.
• W2107931499 hasPublicationYear "2004" @default.
• W2107931499 type Work @default.
• W2107931499 sameAs 2107931499 @default.
• W2107931499 citedByCount "94" @default.
• W2107931499 countsByYear W21079314992012 @default.
• W2107931499 countsByYear W21079314992013 @default.
• W2107931499 countsByYear W21079314992014 @default.
• W2107931499 countsByYear W21079314992015 @default.
• W2107931499 countsByYear W21079314992016 @default.
• W2107931499 countsByYear W21079314992017 @default.
• W2107931499 countsByYear W21079314992018 @default.
• W2107931499 countsByYear W21079314992019 @default.
• W2107931499 countsByYear W21079314992020 @default.
• W2107931499 countsByYear W21079314992021 @default.
• W2107931499 countsByYear W21079314992022 @default.
• W2107931499 countsByYear W21079314992023 @default.
• W2107931499 crossrefType "journal-article" @default.
• W2107931499 hasAuthorship W2107931499A5008114238 @default.
• W2107931499 hasAuthorship W2107931499A5018826785 @default.
• W2107931499 hasAuthorship W2107931499A5023160611 @default.
• W2107931499 hasAuthorship W2107931499A5034956444 @default.
• W2107931499 hasAuthorship W2107931499A5057046852 @default.
• W2107931499 hasAuthorship W2107931499A5064484919 @default.
• W2107931499 hasAuthorship W2107931499A5074376265 @default.
• W2107931499 hasAuthorship W2107931499A5077011016 @default.
• W2107931499 hasAuthorship W2107931499A5077909900 @default.
• W2107931499 hasConcept C119857082 @default.
• W2107931499 hasConcept C127413603 @default.
• W2107931499 hasConcept C138496976 @default.
• W2107931499 hasConcept C138885662 @default.
• W2107931499 hasConcept C15744967 @default.
• W2107931499 hasConcept C160735492 @default.
• W2107931499 hasConcept C162324750 @default.
• W2107931499 hasConcept C163864269 @default.
• W2107931499 hasConcept C1862650 @default.
• W2107931499 hasConcept C2778724333 @default.
• W2107931499 hasConcept C2779891985 @default.
• W2107931499 hasConcept C2780645631 @default.
• W2107931499 hasConcept C41008148 @default.
• W2107931499 hasConcept C41895202 @default.
• W2107931499 hasConcept C50522688 @default.
• W2107931499 hasConcept C61863361 @default.
• W2107931499 hasConcept C71924100 @default.
• W2107931499 hasConcept C78519656 @default.
• W2107931499 hasConcept C83849319 @default.
• W2107931499 hasConceptScore W2107931499C119857082 @default.
• W2107931499 hasConceptScore W2107931499C127413603 @default.
• W2107931499 hasConceptScore W2107931499C138496976 @default.
• W2107931499 hasConceptScore W2107931499C138885662 @default.
• W2107931499 hasConceptScore W2107931499C15744967 @default.
• W2107931499 hasConceptScore W2107931499C160735492 @default.
• W2107931499 hasConceptScore W2107931499C162324750 @default.
• W2107931499 hasConceptScore W2107931499C163864269 @default.
• W2107931499 hasConceptScore W2107931499C1862650 @default.
• W2107931499 hasConceptScore W2107931499C2778724333 @default.
• W2107931499 hasConceptScore W2107931499C2779891985 @default.
• W2107931499 hasConceptScore W2107931499C2780645631 @default.
• W2107931499 hasConceptScore W2107931499C41008148 @default.
• W2107931499 hasConceptScore W2107931499C41895202 @default.
• W2107931499 hasConceptScore W2107931499C50522688 @default.
• W2107931499 hasConceptScore W2107931499C61863361 @default.
• W2107931499 hasConceptScore W2107931499C71924100 @default.
• W2107931499 hasConceptScore W2107931499C78519656 @default.
• W2107931499 hasConceptScore W2107931499C83849319 @default.
• W2107931499 hasIssue "4" @default.
• W2107931499 hasLocation W21079314991 @default.
• W2107931499 hasLocation W21079314992 @default.
• W2107931499 hasOpenAccess W2107931499 @default.
• W2107931499 hasPrimaryLocation W21079314991 @default.
• W2107931499 hasRelatedWork W1966976587 @default.
• W2107931499 hasRelatedWork W1979852909 @default.
• W2107931499 hasRelatedWork W1980457457 @default.
• W2107931499 hasRelatedWork W1984207165 @default.
• W2107931499 hasRelatedWork W1996751524 @default.
• W2107931499 hasRelatedWork W2054015915 @default.
• W2107931499 hasRelatedWork W2330902540 @default.
• W2107931499 hasRelatedWork W2581818947 @default.

• next